This article was originally published in The Tan Sheet
"FDA is planning to conduct studies of the palatability, solubility and stability of KI dissolved in a number of different liquids, including juice and formula," agency says in Q&A document on use of the OTC in radiation emergencies. FDA notes it is working with KI manufacturers to "expedite submission and review" of applications for tablet dosage strengths below 130 mg and to amend "Drug Facts" labeling to incorporate new KI dosing recommendations announced in December (1"The Tan Sheet" Dec. 17, 2001, p. 5). Recommendations generally call for adults 18 and older to take 130 mg/day, children three and older 65 mg/d, children under three 32 mg/d...
You may also be interested in...
Within a year of enacting bioterrorism legislation, the Bush Administration will consult with federal, state and local agencies to establish guidelines for the stockpiling of potassium iodide (KI) tablets
Any facility that manufactures, processes, packs or holds food for consumption in the U.S. would have to register with HHS within 180 days of the enactment of a bioterrorism bill passed by the House Dec. 12
The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval.